Analysis of type I IFN response and T cell activation in severe COVID-19/HIV-1 coinfection: A case report.
Anti-Retroviral Agents
/ therapeutic use
Betacoronavirus
CD4-Positive T-Lymphocytes
/ metabolism
CD8-Positive T-Lymphocytes
/ metabolism
COVID-19
Case-Control Studies
Coronavirus Infections
/ complications
Enzyme Inhibitors
/ therapeutic use
Female
HIV Infections
/ complications
Humans
Hydroxychloroquine
/ therapeutic use
Interferons
/ blood
Lymphocyte Activation
Middle Aged
Pandemics
Pneumonia, Viral
/ complications
RNA, Messenger
Real-Time Polymerase Chain Reaction
SARS-CoV-2
Severe Acute Respiratory Syndrome
/ complications
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
04 Sep 2020
04 Sep 2020
Historique:
entrez:
9
9
2020
pubmed:
10
9
2020
medline:
24
9
2020
Statut:
ppublish
Résumé
Complex immune dysregulation in interferon (IFN) and T cell response has been observed in human immunodeficiency virus (HIV-1)-infected patients as well as in coronavirus disease-2019 (COVID-19) patients. However, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)/HIV-1 coinfection has been described in only few cases worldwide and no data are available on immunological outcomes in HIV-1-patients infected with SARS-CoV-2. Hence, this study aims to compare type I IFN response and T cell activation levels between a SARS-CoV-2/HIV-1-coinfected female patient and age-matched HIV-1-positive or uninfected women. A 52-year-old woman diagnosed with SARS-CoV-2/HIV-1 coinfection, ten HIV-1-positive women and five age-matched-healthy individuals were enrolled in this study. SARS-CoV-2 infection caused severe pneumonia in the second week of illness in HIV-1-positive patient under protease inhibitors. Chest high-resolution computed tomography images of the SARS-CoV-2/HIV-1-coinfected patient showed bilateral ground-glass opacities. SARS-CoV-2/HIV-1-coinfected female patient under darunavir/cobicistat regimen received a 7-days hydroxychloroquine therapy. Analysis of IFNα/β mRNA levels and CD4 and CD8 T cell (CD38, human leukocyte antigen-DR [HLA-DR], CD38 HLA-DR) frequencies were performed by RT/real-time PCR assays and flow cytometry, respectively. Median relative difference (MRD) was calculated for each immunological variable. For values greater than reference, MRD should be a positive number and for values that are smaller, MRD should be negative. The severe pneumonia observed in SARS-CoV-2/HIV-1-positive patient under protease inhibitors was reversed by a 7-days hydroxychloroquine therapy. At the end of treatment, on day 7, patient reported resolution of fever, normalization of respiratory rate (14 breaths/min), and improved oxygen arterial pressure with a FiO2 of 30%. MRD values for IFNα/β and CD4 and CD8 T cells expressing CD38 and/or HLA-DR found in SARS-CoV-2-/HIV-1-coinfected woman were approximatively equal to 0 when refereed respectively to HIV-1-positive female patients [MRDs IFNα/β: median -0.2545 (range: -0.5/0.1); T cells: median -0.11 (range: -0.8/1.3)] and ≥ 6 when referred to healthy individuals [MRDs IFNα/β: median 28.45 (range: 15/41.9); T cells: median 10 (range 6/22)]. These results indicate that SARS-CoV-2 infection in HIV-1-positive female patient was associated with increased levels of IFNα/β-mRNAs and T cell activation compared to healthy individuals.
Identifiants
pubmed: 32899009
doi: 10.1097/MD.0000000000021803
pii: 00005792-202009040-00021
pmc: PMC7478511
doi:
Substances chimiques
Anti-Retroviral Agents
0
Enzyme Inhibitors
0
RNA, Messenger
0
Hydroxychloroquine
4QWG6N8QKH
Interferons
9008-11-1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e21803Commentaires et corrections
Type : ErratumIn
Références
Health Equity. 2020 Apr 17;4(1):139-141
pubmed: 32368712
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Lancet. 2020 May 30;395(10238):1695-1704
pubmed: 32401715
Nat Med. 2020 Apr;26(4):453-455
pubmed: 32284614
J Clin Virol. 2020 Jul;128:104450
pubmed: 32464309
Med Microbiol Immunol. 2019 Oct;208(5):679-691
pubmed: 30564919
Lancet HIV. 2020 May;7(5):e314-e316
pubmed: 32304642
Infection. 2020 Oct;48(5):681-686
pubmed: 32394344
J Infect. 2013 Dec;67(6):606-16
pubmed: 24096239
J Med Virol. 2020 Jun;92(6):529-530
pubmed: 32160316
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
N Engl J Med. 2020 Jun 18;382(25):2411-2418
pubmed: 32379955
Cell Host Microbe. 2020 Jun 10;27(6):883-890.e2
pubmed: 32407669
Immunol Rev. 2013 Jul;254(1):78-101
pubmed: 23772616
J Am Coll Cardiol. 2020 Jun 2;75(21):2746-2748
pubmed: 32330545
Cytokine Growth Factor Rev. 2018 Apr;40:19-31
pubmed: 29576284
Int J Infect Dis. 2020 Jul;96:148-150
pubmed: 32335339
Cytokine. 2019 Aug;120:273-281
pubmed: 30910260
Expert Rev Respir Med. 2016 Apr;10(4):463-472
pubmed: 26918376
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Clin Infect Dis. 2020 Nov 19;71(16):2276-2278
pubmed: 32407467
Thorax. 2004 Mar;59(3):252-6
pubmed: 14985565
Cell. 2020 May 28;181(5):1036-1045.e9
pubmed: 32416070
Clin Infect Dis. 2020 Sep 12;71(6):1400-1409
pubmed: 32270184
Cell Discov. 2020 May 4;6:31
pubmed: 32377375
J Racial Ethn Health Disparities. 2020 Jun;7(3):398-402
pubmed: 32306369
Biol Sex Differ. 2020 May 1;11(1):23
pubmed: 32357901